Close Menu

stock offering

NEW YORK (GenomeWeb News) – Rosetta Genomics on Monday filed a preliminary prospectus with the US Securities and Exchange Commission for a public offering of common stock aimed at raising up to $35 million.

NEW YORK (GenomeWeb News) – GenMark Diagnostics late on Wednesday priced its public offering of 10 million shares at $4.20 per share.

NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market on Tuesday that it intends to sell 10 million shares of its common stock in a public offering.

NEW YORK (GenomeWeb News) – Trovagene announced late on Tuesday the pricing of a public offering of 1.15 million units and said that its shares will begin trading on the Nasdaq Capital Market today under ticker symbol "TROV".

NEW YORK (GenomeWeb News) – Pressure BioSciences has filed with US regulators for a direct offering of a maximum of $5 million of its Series F preferred stock.

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has entered into definitive agreements with investors to purchase $2.2 million worth of its stock.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Complete Genomics today announced an agreement with investment bank MLV & Co. for the potential sale of an aggregate of $30 million of its common stock.

Alnylam to Sell $86.9M in Stock

Premium

Alnylam Pharmaceuticals this week announced that it would offer for sale 8.625 million of its shares at $10.75 per share.
The company's shares have been trading around $12.50 this week.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Sequenom has launched a public offering of 13 million shares of common stock priced at $4.15 per share.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.